Appointment of Jean-Luc Bélingard as Chairman of the Supervisory Board of Biolog-id
4.1.2021 15:58:00 EET | Business Wire | Press release
The members of the Supervisory Board of Biolog-id elected Jean-Luc Bélingard as Chairman of the Supervisory Board of the company. He succeeds to its founder, Jean-Claude Mongrenier, who will assume the vice-presidency. This appointment comes into effect on January 1st, 2021.
Biolog-id has developed unique expertise in connected healthcare solutions and offers a breakthrough innovation that makes the life cycle of sensitive therapeutic products (red blood cell concentrates, platelets, plasma, chemotherapy preparations) more reliable, and secures their administration to patients.
Jean-Luc Bélingard is a seasoned industry leader with an international career in the pharmaceutical, life sciences and diagnostics sector. He comes with 40 years of experience with some of the largest pharmaceutical companies, notably at Roche where he was a member of the Group Executive Committee (Basel, Switzerland). Since 2011, he has served as CEO and then Chairman of bioMérieux before taking on, in 2018, the Vice-Presidency of Institut Mérieux.
"It is an honor and a responsibility for me to join and support Biolog-id in a new stage of its development. Biolog-id is a company with a promising future. It patented a connected solution, Medical Device certified, which offers great added value in terms of public healthcare, with significant economic and social impacts. It makes it possible to strengthen the safety of medical procedures, improve the working conditions of healthcare professionals, reduce operational costs and prevent the loss of sensitive health products. This set of added values is a guarantee of quality and safety for patients and healthcare establishments. By accepting this mandate as Chairman of the Supervisory Board, I hope, along with the management team and employees, to contribute to the success of this innovative company”, declares Jean-Luc Bélingard.
"As the founder of the company, I am happy to hand over my functions to Jean-Luc Bélingard, with whom I share the same vision of the company, based on humanist values. Biolog-id will benefit from its extensive experience in the pharmaceutical industry and its governance skills. In particular, he will be responsible for leading the introduction of Biolog-id on the Nasdaq, its listing being planned as of 2022 ", announces Jean-Claude Mongrenier.
"The appointment of Jean-Luc Bélingard as Chairman of the Supervisory Board will allow Biolog-id to benefit from a high-level leadership executive with an indisputable influence. This is an important appointment for the international development of the company and for its upcoming IPO. I am convinced that he will be able to capitalize on this flagship of the FrenchTech 120 to make it go through new major stages, "confirms Jacques Simonnet, founder of the Xerys Group which has already funded Biolog-id up to about fifty million euros and is preparing a capital increase of more than 20 million euros.
About Biolog-id
Biolog-id has designed an intelligent and patented solution for the management and traceability of sensitive healthcare products (red blood cell concentrates, plasma, platelets, chemotherapy preparations), in order to optimize their supply chain from donor to patient. Present in North America, Europe, the Middle East, India and the Asia-Pacific region, Biolog-id has about a hundred employees around the world. The Biolog-connect® solution is protected by more than 100 international patents. Biolog-id is the property of its founder and the Xerys Funds.
Web site: www.biolog-id.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005413/en/
Contact information
Astrid Billard - astrid.billard@biolog-id.com
Noémie Mourot - no.mourot@gmail.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dream Industrial REIT Announces Entry Into U.K. Multi-Let Industrial Market and Growth of Strategic Private Ventures in Europe31.7.2026 01:06:00 EEST | Press release
Dream Industrial Real Estate Investment Trust (TSX: DIR.UN) (the “Trust” or the “REIT” or “DIR”) today announced that the Trust and Dream Unlimited Corp. (TSX: DRM) (“Dream”), have entered into definitive agreements for Dream to acquire Chancerygate Limited (“Chancerygate” or “CG”), a U.K.-based industrial developer and asset manager with a 30-year track record in the multi-let industrial (“MLI”) sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730297448/en/ Audio Park, Sussex, UK - 104,000 sq ft As part of the transaction, Dream will assume Chancerygate's investment management and development platform. Dream Industrial REIT will acquire Chancerygate's wholly owned real estate assets and co-investment interests across its managed ventures for consideration of approximately £78 million ($147 million), gross of certain in-place debt on the wholly owned real estate assets, and expects to fund an additional £25 million
Rimini Street Announces Fiscal Second Quarter 2026 Financial and Operating Results30.7.2026 23:03:00 EEST | Press release
Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the fiscal second quarter ended June 30, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730702735/en/ Rimini Street Announces Fiscal Second Quarter 2026 Financial and Operating Results “Second-quarter results and four consecutive quarters of improved growth metrics demonstrate strong demand for our core Rimini Support™ offering, increasing adoption of our broader enterprise software services portfolio and improving sales execution,” said Seth Ravin, president and CEO, Rimini Street. “Real innovation is not about installing a software vendor’s next ‘.ai’ release — it is about reducing total operating costs, improving profitability and enhancing competitive
Rimini Street Launches Rimini Govern™ for AI to Deliver Comprehensive AI Agent Governance, Security & Interoperability as a Service30.7.2026 23:01:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced the immediate availability of Rimini Govern™ for AI, the newest offering in the company’s Rimini Govern portfolio of Governance, Risk and Compliance (GRC) solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730389723/en/ Rimini Street Launches Rimini Govern™ for AI to Deliver Comprehensive AI Agent Governance, Security & Interoperability as a Service The new managed service is delivered 24/7/365 through Rimini Street’s Global Command Centers by expert AI engineers to help organizations: Accelerate AI agent deployment Reduce AI agent operational risk Increase visibility into AI agent activity Provide AI agent activity audit capability Control AI agent operating costs Measure business value from AI agent investments Scale AI agent adoptio
One Biosciences Announces Data Validating New Method for Single-Cell Transcriptomic Tumor Profiling from Clinical Pathology Samples30.7.2026 22:03:00 EEST | Press release
One Biosciences, a techbio company pioneering clinical-grade single-cell tumor profiling, today announced data establishing that single-cell RNA expression profiles can be generated from the standard, formalin-fixed paraffin-embedded (FFPE) pathology specimens obtained in routine cancer care using the company’s proprietary platform, OneMap™. The study, conducted with collaborators at Centre Léon Bérard, Hôpital Bichat–Claude Bernard, Institut Curie, and Memorial Sloan Kettering Cancer Center, was released as a preprint on BiorXiv. “Every tumor is a unique ecosystem of many different types of cells, some cancerous, some not. Single cell profiling enables us to understand what those cells are, what they’re doing and potentially how that may impact treatment outcomes,” said Helena Yu, MD, thoracic medical oncologist at Memorial Sloan Kettering Cancer Center. “Until now that type of analysis required different types of samples and workflows than we deploy in clinical care. This study shows
Myers Industries Launches European Production of Scepter Military Packaging30.7.2026 19:04:00 EEST | Press release
Myers Industries, Inc. (NYSE: MYE), a leading manufacturer of Products that Protect™, today announced that its Scepter business has launched production of military ammunition containers in Europe through Scepter International Poland sp z o.o. Production began earlier this year at a privately owned contract manufacturing facility in Poland that was selected by Scepter following a rigorous evaluation process. Initial customer shipments commenced in April 2026. Scepter manufactures a growing portfolio of proprietary ammunition containers using advanced resin compounds. Already fielded by military customers across NATO and allied nations, the ammunition containers are now being produced in Europe to better serve regional demand. Scepter's lightweight, reusable polymer packaging replaces traditional wood and metal containers. The result is improved soldier handling; reduced transportation weight and logistics burden; greater fuel efficiency; lower lifecycle costs; and a durable, corrosion-r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom